Gene Editing Race Between Editas and Vertex, CRISPR Heats Up

The gene editing race between Editas Medicine and Vertex Pharmaceuticals with CRISPR Therapeutics has heated up as both companies released positive data for their sickle cell disease (SCD) and transfusion-dependent beta thalassemia (TDT) hopeful treatments. Editas Medicine unveiled early data from the RUBY and EdiTHAL trials on Friday, demonstrating the potential of its gene editor EDIT-301 in t..